Pro Medicus Gains Momentum Amid Strong Contract Wins and AI Resilience

Pro Medicus, a medical imaging software company, has reassured investors that artificial intelligence (AI) will not negatively impact its subscription-based business model, easing fears of a so-called 'Saaspocalypse'. CEO Dr. Sam Hupert highlighted recent contract wins, including a $16 million, seven-year deal with Tidal Health and an expanded five-year, $28 million agreement with Allegheny Health. These contracts contribute to the company’s $400 million in new deals for the current financial year, making 2025-26 one of the strongest sales periods in its history. Hupert emphasized that there are no plans for workforce reductions or AI-specific hiring, as the company is already leveraging AI tools effectively. Meanwhile, other ASX-listed health companies are seeing notable developments: Chimeric Therapeutics’ CAR-T therapy trial shows promising early results in gastrointestinal cancers, driving a 35% surge in its share price despite a small market capitalization of $7 million. Epiminder has successfully recruited the first 25 patients for its pivotal Minder System epilepsy study, while Adherium’s data reveal that only 8% of asthma patients use inhalers correctly, highlighting ongoing challenges in patient compliance. Cynata Therapeutics received a WHO-recognized generic name for its stem cell therapy, pixenstrocel, and anticipates releasing key phase II and III trial results soon. Overall, the health and biotech sector continues to navigate AI integration, clinical advancements, and patient care challenges.